Rice University scientists have achieved the total synthesis of a scarce natural marine product that may become a powerful cancer-fighting agent – the molecule shishijimicin A.
A group led by world-renowned Rice chemist K.C. Nicolaou announced the successful synthesis this month in the Journal of the American Chemical Society.
The complex organic molecule was discovered in a rare sea squirt, Didemnum proliferum, more than a decade ago. Lab tests at the time proved it to be more than 1,000 times as toxic to cancer cells as the anticancer drug taxol (aka paclitaxel), but its scarcity did not provide amounts sufficient for extensive biological studies and clinical trials.
For that, chemists needed to design and develop the many steps required to synthesize the molecule, a specialty for which Nicolaou is well-known. Nicolaou, who joined Rice in 2013, is noted for achieving the first synthesis of taxol as well as the synthesis of the highly cytotoxic compound calicheamicin, which was used in the first antibody-drug conjugate (ADC) for targeted chemotherapy.
Nicolaou said shishijimicin shows just as much potential – and perhaps more – for cancer treatment via “Trojan horse”-style ADCs tuned to target specific types of cancer. “Because it’s so potent, you may only need one or two molecules to get into a cancer cell to do the job,” he said.
Such toxins kill cancer cells by cleaving their DNA or freezing their cytoskeletons to prevent them from replicating, he said.
The path to synthesis took a rapid two years because much of the groundwork had already been set by Nicolaou’s basic work three decades ago in the total synthesis of calicheamicin.
“All the fundamental science for the shishijimicin project was done in the 1990s,” he said. “What we synthesized then was too toxic to be used, but now it has revitalized the whole field because biologists and clinicians can selectively target cancer cells (with ADCs). If we hadn’t done the fundamental science so many years ago, it would have taken us so much longer to come to the same point.”
Nicolaou said his prime concern, in addition to facilitating biology and medicine, is to advance the field of synthetic chemistry. “If we don’t advance it now, we won’t be able to make the complex molecules of the future,” he said. “We have to continue to sharpen the tools of organic synthesis.”
Nicolaou said the next steps for shishijimicin are to streamline its synthesis and add chemical handles so it can be attached to antibodies for delivery to cancer cells. “We’ve established the beachhead with the first total synthesis,” he said. “Now we aim to optimize the process to make it more practical and apply it to synthesize variations of the molecule.”
Then it will be up to partner pharmaceutical companies to develop the compound for eventual clinical trials. They won’t need much, Nicolaou said. “If they have a few hundred milligrams – a fraction of a gram – they can take it to clinical trials, because it’s so potent,” he said. “And now they have hundreds of antibodies selected for different kinds of cancer. My hope is that our molecule will lead to an effective drug for personalized medicine.”
Rice postdoctoral researchers Zhaoyong Lu, James Woods and Te-ik Sohn and graduate student Ruofan Li are co-authors of the paper. Nicolaou is Rice’s Harry C. and Olga K. Wiess Professor of Chemistry.
The Cancer Prevention and Research Institute of Texas and the Welch Foundation supported the research.
RT @LasAmericasMS: TY @bcmhouston medical Stu 4helping our Ss understand Germs &Hygiene. Learning in a new environment &understanding germ…
10.26, 6-8 pm: Join @MethodistHosp The Woodlands Hospital for a celebration of women’s health & wellness. Register: https://t.co/3syW4qVpnN
Dr. Janet Malek says increased acceptance of gender nonconformity is raising awareness of intersex issues. https://t.co/svkMN2fdS5
Join Houston Methodist The Woodlands Hospital for Positively Pink, a celebration of women’s health & wellness. This free event will be held at Big Sky Barn off ...
MD Anderson Cancer CenterMDAnderson
Cancer doesn't care what kind of boots you wear. Join us at MD Anderson Boot Walk to End Cancer on Saturday, Nov. 11 and help give cancer the boot. Register to...
@VERONICAGODOY04 Safe travels. Let us know if you need anything while you're here.
RT @SurenaMatinMD: Congratulations @ChapinMD for your determination and vision in making this happen #endcancer @MDAndersonNews #ProstateCa…
Tweet #HR4HR to help donate to hurricane relief efforts during the MLB Postseason. https://t.co/291XEy7DqE
Find out which #vaccinations cancer patients receiving treatment may need and when it’s best to get them.… https://t.co/7XCJpeJTlg
Retired Army Veteran saw service as an opportunity for education https://t.co/CJjuYulcuB via @bgdailynews
"Not smoking, watching your weight and continuing to learn new things could help you live longer" https://t.co/T79Uuy786i
RT @McGovernMed: In this week's Study Break, Dean Stoll speaks on team science: https://t.co/PLwJfj4YEG https://t.co/ct46wDXsgc
RT @McGovernMed: UTHealth, Adult Protective Services join forces to improve lives of Texas elderly https://t.co/QTm8Qhs259
RT @McGovernMed: Congratulations Dr. Gerard Francisco, elected to #NAM https://t.co/66e3lWXzhQ https://t.co/LaSwcmeYPw